Industry: Treatment for cardiac disease
CorAmi has developed a new way to treat cardiac diseases. The company’s key innovation is a catheter device that allows therapeutic gels to be placed directly on the surface of the heart. This targeted delivery means the heart receives a sustained dose of the gel while minimizing side effects that are caused by a broader dosing approach, in which the therapy affects the whole body.
The company’s first therapy is aimed at treating atrial fibrillation, an irregular heartbeat that can cause more severe issues like blood clots, heart failure and stroke. The condition affects at least 2.7 million Americans.
Current treatment methods for atrial fibrillation include antiarrhythmic drugs, but conventional dosing causes toxic build-up in the liver, lungs and thyroid. Using CorAmi’s delivery catheter and hydrogel, physicians could deliver these same antiarrhythmic drugs directly to the heart, avoiding those harmful side effects.
CorAmi’s treatment could be applied easily and efficiently during cardiac surgery or other procedures.
Company website: CorAmi